(Total Views: 321)
Posted On: 04/10/2020 8:50:10 AM
Post# of 11803
Abbott’s isn’t immunoassay.. we’ve established you’re spotty on the science here; we can go down this road again, but you’ll just pretend you don’t see my questions when you realize you’ve just said something egregiously wrong.
Abbott is also a behemoth, with an outstanding shares count to match. They’ll get a decent bump for one, two quarters at best, and a small and relatively negligible (WRT their total revenue) increase in diagnostics going forward, but there’s no real opportunity there. Over-priced in.
The need for rapid confirmation of COVID19 is going to be a very short window in the developed world.. 2-3 months most likely. Margins are going to be razor thin in the developig world.
Ultimately, the biggest need going forward will be for antibody / immunity testing, and even that will fade much faster than most people expect.
It’s the difference between being an engineer and a scientist; possibly, maybe, DECN has solved a problem. So, potentially, good engineering. How long will the problem last? Bad science
Abbott is also a behemoth, with an outstanding shares count to match. They’ll get a decent bump for one, two quarters at best, and a small and relatively negligible (WRT their total revenue) increase in diagnostics going forward, but there’s no real opportunity there. Over-priced in.
The need for rapid confirmation of COVID19 is going to be a very short window in the developed world.. 2-3 months most likely. Margins are going to be razor thin in the developig world.
Ultimately, the biggest need going forward will be for antibody / immunity testing, and even that will fade much faster than most people expect.
It’s the difference between being an engineer and a scientist; possibly, maybe, DECN has solved a problem. So, potentially, good engineering. How long will the problem last? Bad science
(0)
(1)
